Text Size

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Instituto Oftalmologico Gomez-Ulla, Calle Maruxa Mallo 3 Santiago de Compostela, Galicia, Spain; LLC Vzglyad, Leningradskaya, Chita, Russia; Santen SA, Geneva, Switzerland; Tutkimusz Ltd, Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary

Related Publications

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022